Lidocaine for dinutuximab-associated pain? A multicenter retrospective observational cohort study.
Julianna FeatherlySarabeth Baxter WojnowiczKelly SteidlJeni BurgessPublished in: Pediatric blood & cancer (2022)
This study did not find a statistically significant difference in morphine equivalents between patients receiving i.v. lidocaine and those who did not. Lidocaine use resulted in a statistically significant lower dinutuximab infusion time. Our data suggest it is a safe adjuvant medication, for use outside of the pediatric intensive care unit, in the treatment of dinutuximab-associated neuropathic pain.
Keyphrases
- big data
- neuropathic pain
- artificial intelligence
- intensive care unit
- machine learning
- spinal cord
- spinal cord injury
- cross sectional
- early stage
- healthcare
- chronic pain
- low dose
- pain management
- emergency department
- combination therapy
- adverse drug
- electronic health record
- replacement therapy
- young adults
- childhood cancer
- data analysis